close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.170 +0.280 (+4.75%)
Official Closing Price Updated: 8:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
41 42 Next >
News headline image
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From March 6, 2023 ↗
 
Via Benzinga
News headline image
Cybin, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions
Via Investor Brand Network
News headline image
Cybin Inc. Was Down 70% In 2022 But Has Bounced Back By 59% YTD - Here's Why ↗
A review of Cybin Inc.'s latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock over the next 12 months. 
Via Talk Markets
News headline image
Cybin: Positive Clinical Trial On Psilocybin Analog For Major Depression & Updates On DMT Analog Program ↗
Psychedelics biotech company Cybin Inc. 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From March 2, 2023 ↗
 
Via Benzinga
News headline image
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
From Cybin Inc.
Via Business Wire
News headline image
Cybin, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 28, 2023 ↗
 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Progress Updates on Two Clinical Development Programs
Via Investor Brand Network
News headline image
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 27, 2023 ↗
 
Via Benzinga
News headline image
"Multi-Bagger" Portfolio Outperforming "Rags-To-Riches" Portfolio By 2-To-1 Margin YTD ↗
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but perhaps some will bounce back with 
Via Talk Markets
News headline image
Of The 6 Largest Psychedelic Drug Stocks, Only One Has Not Advanced YTD ↗
The most critical financial information on the health of a company is whether, or not, it has a Net Positive Operating Cash Flow; its Altman -Z Score; its Piotroski F-Score; and the percentage... 
Via Talk Markets
News headline image
Only 2 Of 5 Cannabis Categories Have Advanced YTD ↗
The 5 categories in the cannabis sector perform quite differently from each other but YTD the common trend is mostly downward. 
Via Talk Markets
News headline image
Psychedelic Stock Gainers And Losers From February 24, 2023 ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 23, 2023 ↗
 
Via Benzinga
News headline image
Cybin Stock Down On Laying Off 15% Of Workforce As Part Of A Streamlining Clinical Alignment ↗
Cybin Inc. (NEO:CYBN) (AMEX:CYBN) announced Thursday a streamlining plan aimed at maximizing the company’s operating efficiency and allowing it to focus on critical clinical trials. 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
News headline image
Psychedelic Stock Gainers And Losers From February 22, 2023 ↗
 
Via Benzinga
News headline image
Cybin Announces Streamlined Clinical Alignment
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 21, 2023 ↗
 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From February 20, 2023 ↗
 
Via Benzinga
News headline image
"Multi-Bagger" Portfolio Outperforming "Rags-To-Riches" Portfolio YTD By A 2-To-1 Margin ↗
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022. Perhaps some will bounce back with 
Via Talk Markets
News headline image
6 Largest Psychedelic Stocks Showing Strength; Up 11.5% YTD ↗
A look at the performance of the six largest psychedelic stocks by market capitalization. 
Via Talk Markets
News headline image
ATAI Life Sciences, GH Research Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
News headline image
Cybin, Compass Pathways Among Top Psychedelic Movers Of Today ↗
 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today